This sector is booming - but have investors missed the boat?

Biotech and healthcare sectors have experienced a significant valuation recovery following a period of volatility caused by rising interest rates, political uncertainty, and post-pandemic corrections. This resurgence is largely fueled by intense M&A activity, as major pharmaceutical companies seek to mitigate a massive "patent cliff" by acquiring innovative, clinically de-risked assets. Elsa Craig, manager of the International Biotechnology Investment Trust, highlights that successful investment in this space requires a diversified "basket" approach to manage binary risks associated with clinical trials. While oncology and personalized mRNA cancer vaccines present high-growth opportunities, antibiotic development remains stagnant due to inherent commercial and ethical challenges. Investors should view the sector as a long-term, volatile play where professional management is essential to navigate the complex interplay of scientific innovation, regulatory hurdles, and evolving market valuations.